Cure My Disease

Don't miss your cure!

 Log in / Sign up

One visit, two shots: study tests combining RSV and COVID vaccines for seniors

NCT ID NCT06374394

Completed ⭐️ VACCINE ⭐️ Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 3 trial tested whether giving an RSV vaccine and a COVID-19 mRNA vaccine at the same time is as safe and effective as giving them separately. About 841 adults aged 50 and older took part. Researchers measured immune responses and side effects one month after vaccination. The goal is to see if combining the shots is a practical option for protecting older adults against both respiratory viruses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
RSVPreF3 OA investigational vaccine and COVID-19 mRNA vaccine (Omicron XBB.1.5)
What this could lead to
If successful, this could show that getting both vaccines at the same visit is safe and effective, making it more convenient for older adults to protect against RSV and COVID-19.
What could go wrong
This is a completed phase 3 trial, but results are not yet published. The study only looks at immune response and short-term safety, not long-term protection. Co-administration might still cause more side effects than separate shots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

Contacts and locations

Locations

  • GSK Investigational Site

    Coral Gables, Florida, 33134, United States

  • GSK Investigational Site

    Savannah, Georgia, 31406, United States

  • GSK Investigational Site

    Evansville, Indiana, 47714, United States

  • GSK Investigational Site

    Omaha, Nebraska, 68134, United States

  • GSK Investigational Site

    Rochester, New York, 14609, United States

  • GSK Investigational Site

    Winston-Salem, North Carolina, 27103, United States

  • GSK Investigational Site

    North Charleston, South Carolina, 29405, United States

  • GSK Investigational Site

    Newport News, Virginia, 23606, United States

  • GSK Investigational Site

    Antwerp, 2000, Belgium

  • GSK Investigational Site

    Edegem, 2650, Belgium

  • GSK Investigational Site

    Ghent, 9000, Belgium

  • GSK Investigational Site

    Kluisbergen, 9690, Belgium

  • GSK Investigational Site

    Mechelen, 2800, Belgium

  • GSK Investigational Site

    Breda, 4818 CK, Netherlands

  • GSK Investigational Site

    Enschede, 7512 KZ, Netherlands

  • GSK Investigational Site

    Utrecht, 3584 BA, Netherlands

  • GSK Investigational Site

    Zutphen, 7207 AE, Netherlands

  • GSK Investigational Site

    A Coruña, 15006, Spain

  • GSK Investigational Site

    Barcelona, 08023, Spain

  • GSK Investigational Site

    Barcelona, 08907, Spain

  • GSK Investigational Site

    Boadilla Del Monte Madrid, 28660, Spain

  • GSK Investigational Site

    Madrid, 28040, Spain

  • GSK Investigational Site

    Madrid, 28041, Spain

  • GSK Investigational Site

    Madrid, 28222, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.